Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Liquidia Technologies Inc logo
LQDA

Liquidia Technologies Inc

MaveScore 41 Low model confidence
Last Price US$71.77 As of Jun 15, 2026
Market Cap US$5.4b Company size context
7D Performance 12.28% Past 7 days
1Y Performance 360.06% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2026

77 days old

Market price date

Jun 15, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 41 Low confidence

Stored data quality

Freshness and coverage checks

Latest stored fundamentals and price inputs are recent enough for normal research review.

16/16 Current stored snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

7/35 Weak

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

19/25 Strong

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

0/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

15/15 Strong

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.
  • Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Deep..lue Prediction Screener Map

Liquidia Technologies Inc Overview

Industry: Biotechnology

Sector: Healthcare

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Liquidia Technologies Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Liquidia Technologies Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



Liquidia Technologies Inc Competitors

Liquidia Technologies Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Liquidia Technologies Inc

US$71.77

US$5.4b

12.28%

360.06%